Clinical Trial Update: Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib with or without celecoxib in Stage IIIB-IV non-small cell lung cancer has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Tarceva (erlotinib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-03-01